We aimed to elucidate the role of vitamin D supplementation on adipokines through a systematic review and a meta-analysis of randomized placebo-controlled trials (RCTs ). Sensitivity analysis showed that this effect size is sensitive to one of the studies; removing it resulted in a significant reduction in plasma leptin levels (MD: -12.81%, 95%CI: -24.33, -1.30, p=0.029). In meta-regression, changes in plasma leptin concentrations following vitamin D supplementation were found to be independent of treatment duration (slope: -1.93; 95%CI: -4.08, 0.23; p=0.080). However, changes in serum 25(OH)D were found to be significantly associated with changes in plasma leptin levels following vitamin D supplementation (slope: 1.05; 95%CI: 0.08, 2.02; p=0.033). In conclusion, current data did not indicate a significant effect of vitamin D supplementation on adiponectin and leptin levels.
INTRODUCTION
Vitamin D, a fat-soluble vitamin, plays an important role in bone metabolism and calcium homeostasis [1] . However it has been increasingly recognized that vitamin D deficiency may play a role in several health conditions including cardiovascular disease (CVD) risk. Vitamin D can be present in two hormone precursor forms: ergocalciferol (vitamin D2), found in plants and cholecalciferol (vitamin D3) found in oily fish or synthesized by the skin from 7-dehydrocholesterol during exposure to ultraviolet (UV) rays in sunlight [2] . Both D2 and D3 can be ingested in the form of supplementation or fortified foods. Ergocalciferol and cholecalciferol are then hydroxylated in the liver to form 25-hydroxycholecalciferol (calcidiol or 25(OH)D), which is the best biomarker of vitamin D stores and used to determine sufficiency/deficiency states. Calcidiol is transported to the proximal tubules of the kidneys, where it is hydroxylated by a 1α-hydroxylase enzyme (gene: CYP27B1) to form calcitriol (1,25-dihydroxycholecalciferol and abbreviated to 1,25(OH)2D), the biologically active form of vitamin D [3] ; this process is a tightly regulated by parathyroid hormone levels and serum calcium and phosphorous levels.
The biological actions of 1,25(OH)2D) are mediated through the vitamin D receptor (VDR), a member of the nuclear receptor superfamily, which are widely expressed throughout human tissues: adipocytes, smooth muscles, skin, cells of the immune system, colon, pancreatic β-cells, keratinocytes, osteoblasts and the vasculature [4] . Emerging evidence has suggested a link between vitamin D deficiency and CVD risk, diabetes mellitus (DM), hypertension and dyslipidemia [5] . Lower concentrations of circulating 25(OH)D were associated with higher fasting glucose levels, reduced insulin sensitivity, and increased risk of type 2 DM [6] .
Furthermore, many clinical studies showed that serum 25(OH)D concentrations are inversely correlated with body mass index (BMI), fat mass or percentage of body fat and waist circumference [4] . Recently, the role of vitamin D in the regulation of adipogenesis and thereby in the control of energy homeostasis has become another highly debated issue [7] .
Adipose tissue secretes bioactive peptides, termed adipokines, including leptin and adiponectin, which play an important role in the regulation of energy homeostasis by influencing several biological processes, such as food intake, insulin action, lipid, and glucose metabolism, regulation of energy balance, coagulation, angiogenesis and vascular remodeling [8] . Altered levels of adipokines have been implicated in the pathogenesis of insulin resistance, dyslipidemia and atherosclerosis [9] . Adiponectin is a protein hormone that modulates a number of metabolic processes, especially carbohydrate and fatty acid metabolism [10] . It has anti-atherosclerotic, as well as anti-inflammatory and anti-diabetic properties [11] . According to recent findings, hypoadiponectinemia can increase the risk of metabolic syndrome and coronary artery disease [12, 13] . Moreover, the secretion of adiponectin decreases with obesity and increases with body mass reduction [14] . It has been shown that the reduction of adiponectin concentrations is correlated with insulin resistance and hyperinsulinemia [15] . Another adipokine, leptin, acts on specific receptors in the hypothalamus to decrease appetite and to increase energy expenditure when body fat store is increased. Elevated serum leptin levels signal excessive energy storage to the central nervous system to suppress food intake and increase energy consumption [16] . Vitamin D supplementation might have different effects on adipokine homeostasis.
Experimental data suggested that vitamin D supplementation regulates the expression of adipokines in visceral fat [17] . Moreover, it has been shown that serum 25(OH)D levels are positively correlated with the plasma levels of adiponectin [18] . Some studies reported that vitamin D may decrease the plasma levels of leptin, while others demonstrated an increase production of leptin after vitamin D supplementation. Thus, the data regarding the effects of vitamin D on adipokines are controversial. Therefore, we performed a systematic review of the literature and a meta-analysis of randomized placebo-controlled trials to elucidate the impact of vitamin D supplementation therapy on plasma adipokines concentrations.
METHODS

Search strategy
This study was designed according to the guidelines of the 2009 preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement [19] . PUBMED, Scopus, Web of Science (WoS) and Google Scholar databases were searched using the following search terms in 
Study Selection
Original studies were included if they met the following inclusion criteria: observational studies with case-control, cross-sectional or cohort design, and, (iv) lack of sufficient information on baseline or follow-up adipokine concentrations.
Data extraction
Eligible studies were reviewed and the following data were abstracted (MD and MCS): 1) first author's name, 2) year of publication, 3) country were the study was performed, 4) study Data extraction was performed independently by 2 reviewers; disagreements were resolved by a third reviewer.
Risk of bias assessment
According to the Cochrane Collaboration [20] , a specific tool for assessing risk of bias in each involved study comprises judgment of specific features of the study. This involves evaluating the risk of bias as 'low risk', 'high risk or 'unclear risk'. The last category presents either lack of information or uncertainty over the potential for bias. There are seven checked areas including: sequence generation (selection bias), allocation sequence concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias) and other potential sources of bias.
Risk-of-bias assessment was performed independently by 2 reviewers; disagreements were resolved by a third reviewer.
Quantitative Data Synthesis
Meta-analyses were conducted using Comprehensive Meta-Analysis (CMA) V2 software (Biostat, NJ) [21] . Net changes in measurements (change scores or mean differences [MD]) were calculated as follows: measure at end of follow-up − measure at baseline. All values were collated as percent change from baseline in each group. Standard deviations (SDs) of the MD were calculated using the following formula: SD = square root [(SDpre-treatment) 2 + (SDpost-treatment) 2 -(2R × SDpre-treatment × SDpost-treatment)], assuming a correlation coefficient (R) = 0.5. Where standard error of the mean (SEM) was only reported, standard deviation (SD) was estimated using the following formula: SD = SEM × sqrt (n), where n is the number of subjects.
Net changes in measurements (change scores) were calculated for parallel trials, as follows:
(measure at the end of follow-up in the treatment group − measure at baseline in the treatment group) − (measure at the end of follow-up in the control group − measure at baseline in the control group). A random-effects model and the DerSimonian-Laird method were used to compensate for the heterogeneity between studies in terms of study design, treatment duration, and the characteristics of populations being studied [22] . Inter-study heterogeneity was assessed using Cochran Q test and I 2 index. In order to evaluate the influence of each study on the overall effect size, sensitivity analysis was conducted using leave-one-out method, i.e. iteratively removing one study each time and repeating the analysis.
Meta-regression
A weighted random-effects meta-regression using unrestricted maximum likelihood model was performed to assess the association between the overall estimate of effect size with potential moderator variables including duration of supplementation, baseline serum 25(OH)D and changes in serum 25(OH)D concentrations.
Publication bias
Potential publication bias was explored using visual inspection of Begg's funnel plot asymmetry, and Begg's rank correlation and Egger's weighted regression tests. Duval and
Tweedie "trim and fill" method was used to adjust the analysis for the effects of publication bias [23] .
RESULTS
Search results and trial flow
The initial screening for potential relevance removed the articles whose titles and/or abstracts were obviously irrelevant. After assessment, 9 RCTS with 10 treatment arms achieved the inclusion criteria and were selected for the final meta-analysis [24] [25] [26] [27] [28] [29] [30] [31] [32] . 7 RCTs (7 treatment arms) determined plasma adiponectin concentrations and 5 RCTs with 6 treatment arms evaluated plasma leptin concentrations. A study flow chart is presented in Figure 1 .
In the selected studies, 248 participants were allocated to vitamin D Table 1 . No adverse events related to the supplementation were reported.
Risk of bias assessment
We observed an unclear risk of bias regarding sequence generation, allocation concealment and blinding of outcome assessment in some of the studies, but studies were low-risk in terms of other sources of bias. The systematic assessment of bias in the included trials is presented in Table 2 .
Effect of vitamin D supplementation on plasma adiponectin concentrations
Meta-analysis of data from 7 treatment arms did not suggest a significant alteration in plasma (Figure 2A) . The pooled effect size was robust and remained significant in the leave-one-out sensitivity analysis ( Figure 2B) (Figure 6C ).
Publication bias
Visual inspection of funnel plots suggested asymmetry in the meta-analyses of vitamin D and adipokines that was addressed by imputing one (for adiponectin) and three (for leptin) potentially missing studies using "trim and fill" method. The corrected effect sizes were calculated to be 4.17 (95% CI: -3.28, 11.62) (for adiponectin) ( Figure 7A ) and -13.97 (95% CI: -37.88, 9.93) (for leptin) ( Figure 7B ). The preliminary results obtained in a prior meta-analysis on 6 RCTs suggested a potential increase of serum adiponectin after vitamin D supplementation [33] . Those results had indicated a significant dose-response relationship between vitamin D supplementation and adiponectin levels [33] . However, that meta-analysis collected data only from one database (PubMed), had very small number of participants, and the final results are still not available. In comparison, our meta-analysis is larger, used multiple datasets, and performed rigorous statistical analyses including sensitivity analyses and assessment of risk of bias. [34] . It has been noticed that serum leptin levels and adipose leptin mRNA transcript significantly increase after one-week treatment with vitamin D analog RO-27-5646 [34] . These data showed that 1,25(OH)2D stimulated the production of adipose leptin production in a vitamin D receptor-dependent manner, suggesting that vitamin D may modify the energy homeostasis via direct regulation of leptin expression [34] . In contrast, an in vitro study showed that the treatment of human adipose tissue cultures with 1.25(OH)2D3 for up to 96 h inhibited leptin secretion at 72-92 h, suggesting an indirect effect of vitamin D on leptin regulation [35] . Supplementation with vitamin D significantly elevated serum leptin concentrations in asymptomatic vitamin D-deficient subjects [36] . These results were in agreement with those published by Maggi et al. [28] and Ghavamzadeh et al. [31] .
The results of Egger
It might be assumed that a low intake of vitamin D may be associated with low leptin concentrations, increased appetite and weight. Indeed, the mechanism by which vitamin D supplementation may increase the serum leptin levels and reduce weight seems to be related to the bidirectional adipoinsular axis involving appetite suppression, regulation of insulin secretion and increased glucose uptake [37, 38] . Besides that, a growing number of epidemiological studies have shown an inverse correlation between BMI and serum levels of 25(OH)D in humans. In the same manner, Vilarrasa et al. also obtained an inverse correlation between BMI, body fat, waist, hip circumference and serum levels of 25(OH)D and leptin in a healthy population [39] .
However, no significant associations were observed between serum levels of 25(OH)D and other adipokines measured such as resistin, interleukin-18 and adiponectin [39] . Vitamin D may also be involved in the regulation of adiponectin levels through modification of insulin sensitivity.
Baziar et al. [24] reported significantly increased levels of 25(OH)D and decreased levels of fasting serum glucose, insulin and insulin resistance (p = 0.04, 0.02 and 0.007, respectively) after vitamin D supplementation. However, supplementation with vitamin D in a therapeutic dose had no effect on serum adiponectin concentrations. It appears likely there the measurement of total adiponectin level might be a significant limitation for this study. It should be noted that two forms of circulating adiponectin were measured -low-molecular weight (LMW) and highmolecular weight (HMW) adiponectin. The second one is the active form and the ratio of HMW to total adiponectin is considered more accurate for the assessment of the insulin resistance and adiponectin association [40] . However, in the first study, supplementation with vitamin D did not normalized serum adiponectin levels, while the second study had a small sample size and a control group was absent.
The positive association between vitamin D supplementation and serum adiponectin concentrations observed in cross-sectional studies may be caused by increased expression of adiponectin gene or changes of activity of the renin-angiotensin-aldosterone system [42] .
Activated vitamin D is a negative inhibitor of the renin-angiotensin-aldosterone system. It has been shown that increased activity of the renin-angiotensin-aldosterone system is associated with increased angiotensin production, leading to decreased serum adiponectin concentrations.
Therefore, vitamin D may increase serum adiponectin concentrations through decreasing the angiotensin production [43] . Another possible mechanism explaining the association between vitamin D and adiponectin is the regulation of the adiponectin gene expression through 1,25(OH)2D3, the active form of vitamin D, which has receptors located in preadipocytes [44] .
Furthermore, 1,25(OH)2D3 might play an important role in regulation of tumor necrosis factor-α production which is involved in adiponectin synthesis [45] [46] [47] [48] .
The present meta-analysis has some limitations. First, the qualified RCTs generally had very modest populations (none recruited more than 100 patients) and limited follow-up. Second, the studies involved were heterogeneous concerning the population similarities (age), the duration of the study as well as type and dose of vitamin D. Third, the relationship between all adipokines with vitamin D could not be performed because of the relatively small number of available studies. There is also no information in the included studies on the seeasonal's vitamin D changes.
In conclusion, this meta-analysis did not find a significant effect of supplementation and 
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